

---

# Index

- acanthosis** 207-208  
**acetaldehyde** 98-100, 111-112, 176  
**Act on Prevention of Use of Tobacco (Iceland)** 328  
**β-actin gene** 210, 212-213  
**addiction**  
    to cigarettes 219, 223-224, 227, 229-230, 233, 239-243  
    to nicotine 153, 219-224, 227, 229, 239-242, 279, 282-283, 285, 291-293, 330  
    to ST 219-224, 227, 239-244, 282-283, 285, 291-293  
    to ST, baseball players 32, 35  
**addiction level assessment** 285  
**additives to ST** 97, 106, 136, 348  
**adolescents**  
    attitudes about smoking and ST 261-263, 268, 272-273, 284  
    cessation programs 287  
    knowledge of ST health risks 11, 15-16  
    males, ST use 279  
    marketing of ST to 251, 316  
    oral lesions 13-14  
    preventive ST education 248-249, 253-254  
    smoking 260-263, 268-269  
    smoking prevention 249, 260-263, 266-267  
    ST intervention 280  
    ST prevention programs 260-261, 268-273, 287  
    ST use iv, x, 3-5, 251-253, 268-273, 317, 330, 338, 340-341  
    surveys 346  
**Adult Use of Tobacco Survey (1986)** 243  
**advertising**  
    ban 4, 11, 247, 348  
    of ST iii, vi, ix-x, xii, xiv, 247, 250-251, 318-319, 347  
    of ST, in India 19, 22-23  
    tobacco 324, 328  
    tobacco companies 4  
**age of ST users** 4-5, 8, 253-254, 271, 338, 340-341  
    associated oral cancer patients 91-92, 138  
    baseball players 27-29, 32-34, 67-68, 81  
    baseball players, first use 26, 29-30, 32-34  
    initiation of ST use 45, 47, 253, 268  
    Swedish male snuff users 74-76  
**alcohol and ST use** 13, 27-28, 71, 135, 175, 179-181, 183, 187-189, 202  
**aldehydes** 96, 100, 142, 144  
**alkaloids in moist snuff** 106  
**alveolar lesions** 94  
**American Academy of Otolaryngology-Head and Neck Surgery** 92, 286, 298  
**American Cancer Society** 280, 287, 292-293, 333  
**American Dental Association** 286, 298  
**American Stop Smoking Intervention Study for Cancer Prevention (ASSIST)** xiv, 298, 331, 333  
**amino acids in tobacco** 101, 136  
**amplification**  
    DNA, head and neck tumors 121-122  
    gene 121, 125, 128, 131, 137  
    HPV DNA 178  
    oncogene 121, 123, 125, 129-132, 134, 136-137, 146  
    PCR 134, 183-189  
**α-angelica lactone** 97, 99, 111-112  
**β-angelica lactone** 97, 99, 111-112  
**anogenital cancer** 176, 178  
**anogenital infection** 187-188  
**antigen expression, Langerhans cells** 67  
**antitobacco laws, U.S.** ix  
**antitobacco legislation, Ireland** 323-325  
**areca nut** 20-23, 51-52, 54, 58, 136  
**Asians, ST use** 28  
**assays**  
    DNA transfection 119-120, 137-138  
    lipid 194-195  
    nude mice tumorigenicity 120, 136-137  
    of ST in oral cavity 109  
    perinatal carcinogenesis 166  
    protein kinase C 193-195  
    transfection 123, 129, 136-138  
**ASSIST**  
    *see American Stop Smoking Intervention Study for Cancer Prevention*  
**Astros** 269, 271  
**athletic performance, effect of ST on** 223  
**attitudes about smoking, adolescents** 261-263  
**attitudes about ST use** 268, 272-273  
**baijar** 51, 62  
**ban on ST advertising** iii, xiv, 347  
**ban on ST products** 347  
    by countries 318, 327  
    Ireland 323-325  
    WHO recommendations 315, 318  
**basal cell hyperplasia** 66, 68-69, 71, 178-179  
**baseball players** iv, 26-36, 41-49, 260, 268-273  
    age 27-29, 32-34  
    age of first use 26, 29-30, 32-34  
    associated oral lesions 41-49, 66-72, 78-86  
    attempts to quit 26, 33, 35-36  
    brand of used 27-31, 33

comparison of seasonal and year-round use 26, 29, 31-33, 35  
 cotinine levels 222  
 duration of use 30  
 epithelial changes in lesions 66-72  
 health effects of ST use 223  
 oral biopsies 178  
 patterns of ST use 26-36  
 perception of health effects 26, 33, 35  
 periodontal effects 78-86  
 prevalence of ST use 34-35, 249, 287-288  
 race 27-29, 32, 34  
 ST addiction 224, 227  
 ST cessation 287-288  
 ST prevention 249, 253, 260, 268-273  
*(see also Little League; Major League Baseball)*

**"Beat the Smokeless Habit"** iv

**benzo[a]pyrene (B[a]P), in ST** 96-97, 99, 153, 161, 166-167, 176  
 cocarcinogenicity 112, 202, 204, 206-207, 211

**betel quid chewing** 19-24, 51-62, 136-137, 308

**bidi smoking** 24, 54-55, 308

**bioassays**  
 of ST in oral cavity 109-111, 115  
 perinatal carcinogenesis 164  
 transplacental NNK 164

**blacks** 270  
 baseball players, ST use 28, 32, 34, 81  
 oral cancer, ST use 91

**bladder, cancer of** 175

**blood nicotine levels** 219-224, 226-227, 236, 239-242

**brain, actions of nicotine in** 219, 229-235

**brands of ST** 4, 8, 41-42, 44-49  
 used by baseball players 26-31, 33, 36

**Bruton** 4

**buccal carcinoma** 57

**buccal effects of ST use** 67, 78-85

**buccal lesions** 94

**buccal mucosa** 129  
 effect of nicotine on 157, 159

**buccal mucosal cancer** 11-14

**buccal mucosal lesions** 52-54, 56, 58

**buccal pouch carcinoma** 111

**buccal pouch mucosa, hamsters** 202-208

**Bull of the Woods** 4

**c-myc gene, oncogene, and proto-oncogene** 131, 210  
*(see also myc)*

**cancer**  
*see specific sites, e.g., oral cancer*

**cancer risks associated with ST use,**  
**knowledge about** 11, 15-16

**carcinogenesis of oral cavity**  
 role of viruses 202-214

**carcinogenesis of ST** 109  
 role of nicotine 153-159

**carcinogenesis, perinatal** 161-169

**carcinogens**  
 in chewing tobacco 96, 99, 112  
 in smoking tobacco 175-176  
 in snuff 100  
 in ST 66, 96, 98, 100, 105, 111, 153, 155-156, 161, 163-169, 175-176, 192  
 in tobacco 99, 102, 128, 136, 156, 202, 211  
 newborn sensitivity to 163  
 transplacental 161-162, 164-166

**carcinoma in situ** 91, 93, 208

**carcinoma, oral**  
*see oral cancer*

**carcinomas of head and neck** 119, 122, 125

**carcinomas of oral cavity** 94

**cardiovascular effects of nicotine** 219, 225-226

**cardiovascular effects of ST use** 219, 225-226

**case control studies** 345

**cell lipids** 191-192, 195-197, 199-200

**cell modulators** 191-192, 195-200

**cell response to tobacco components** 191-200

**cell signaling** 192, 195, 199-200

**cellular DNA** 204, 209-211

**central nervous system**  
 action of nicotine in 226, 229-235  
 effects of nicotine on 291-292, 294  
 nicotinic receptors 230-234

**cervix**  
 cancer of 71-72, 176, 179, 183, 185, 202, 214  
 HPV infection 68, 179-180, 187, 189, 203  
 lesions of 189

**cessation camps, India** 310

**cessation counseling, dentists** 297-304

**cessation methods** 331

**cessation of cigarette smoking** 75, 219, 233, 235-237, 239, 243-244, 279, 281-284, 292-293

**cessation of ST use** 219, 223, 235-237, 239, 243-244, 253, 279-288, 291-295, 297-304, 341-348  
 adoption of smoking cessation procedures 279, 281-285, 295  
 clinical studies 280-281  
 compared to smoking 239, 243-244, 282-284  
 cue extinction procedures 280-281  
 dental counseling 297-304  
 India 24  
 motivation 282, 284, 286, 288  
 public health interventions 280, 286-288  
 quit attempts 282-283  
 readiness to quit 285  
 relapse 229, 236, 281, 283  
 special populations 279, 287  
 use of cigarettes 283-284  
 withdrawal symptoms 282-283

**cessation of tobacco use** 219, 229, 235-237, 239, 243-244  
 India 310-311  
 relapse 229, 236, 281, 283

**Chattanooga Chew** 4

- chewing tobacco**  
addiction to 32  
and oral cancer, India 128, 135-136, 138  
and oral epithelial changes 66, 69, 71  
associated lesions 66-67, 69, 71  
baseball players' use 42-49  
brands used by baseball players 28-31, 33  
cancer risk 109, 113  
carcinogenic potential xiv  
carcinogens in 96, 99, 112  
compared to snuff 26, 32-36, 66-67, 69, 71  
consumption v, x-xi  
current use 254  
description of 3  
historical overview ix-xi  
India 19-23, 51-52, 60, 308  
nicotine absorption 219-222  
nicotine content 219  
nitrosamines in 101-103  
plasma cotinine levels 220, 222-223  
prevalence in U.S. 6, 338  
professional baseball players 28-36  
substitutes 283-284  
types, India 20-23  
types of, U.S. 3, 96
- children, ST use** iii-iv, 4-5, 316, 338  
*(see also adolescents)*
- cholesterol** 192, 196, 198-199, 225
- chromosomal abnormalities** 179
- chromosomal translocation** 128, 179
- chromosome 11** 121, 125, 134, 179
- chromosomes** 123, 176, 179-180
- chutta** 308
- cigarette smoking**  
addiction to 219-224, 227, 229-230, 233, 239-243  
adolescents 260-263, 268-269  
adverse health effects 219, 225-227  
advertising ix-x  
and cancer of cervix 71  
blood nicotine levels 220-222, 227, 242  
cancers from 13, 161, 175  
carcinogens 175-176  
cessation of 75, 219, 233, 235-237, 243-244, 279, 281-284, 292-293  
compared to ST use 175, 219-227, 239-244  
concomitant with ST use 8, 19-21, 27-28, 71, 135, 224, 283-284, 286-287  
consumption of x, xiii  
control of 317, 319, 338, 341  
dependence on 223-224, 227, 229-230, 233, 239, 243  
during ST cessation 283-284  
historical overview ix-x, xxxix, 3-4  
India 19-21, 51, 53, 56, 307-308  
intervention 330-331  
legislation 317  
link with cancer 330  
model of social psychological processes 264
- NCI xiv, 330-333  
nicotine absorption 219-222, 240-242, 282-283, 292, 298  
nicotine content of cigarettes 219  
perinatal effects 163  
prevention programs 247-249, 260-263, 266-267, 307  
relapse 229, 236, 281, 283  
ST as substitute for 75  
Sweden 74-75  
withdrawal effects 239, 243-244
- cocarcinogenicity, viruses** 202-214
- college students, ST use** 5
- colon cancer** 135, 179-180
- communication models** 264, 266-267
- communication modes, tobacco use intervention, India** 308-310
- Community Intervention Trial for Smoking Cessation (COMMIT)** 298, 331, 333
- Comprehensive Smokeless Tobacco Act (1986)** iii
- Comprehensive Smokeless Tobacco Health Education Act of 1986** xiv
- concurrent cigarette smoking and ST use** 8, 27-28, 135, 224, 283-284, 286-287
- Conference on a Tobacco-Free New Europe** 320
- conferences on ST** xii, 4, 320, 337-340
- consensus sequence primers** 183-186
- Consensus Development Conference on Smokeless Tobacco (1986)** xii, 4, 337-340
- control of smoking** 338, 341
- control of ST** iii, 247, 337-348  
Ireland 318, 323-329  
legislation 316-319  
WHO recommendations 315-316, 318  
*(see also preventive education programs)*
- control of tobacco** 340-348
- Copenhagen (snuff)** 4, 28, 30-31, 33, 36, 44, 46, 48-49, 68, 285
- coronary artery disease** 219, 225-226
- cotinine levels in ST users** 220, 222-223, 282, 285, 292-294
- cotinine levels of baseball players** 26-27, 29, 31-36
- coumarins** 97-100, 111-112
- creamy snuff** 23, 51, 62
- crotonaldehyde** 98-99, 111-112, 176
- Current Population Survey** xii, xiv
- cytochrome P<sub>450</sub>** 145, 150, 162, 166-168, 176
- dental effects of ST use** 41, 74-76, 78-86, 282, 297
- dental intervention** 286-288, 297-304
- Dental Snuff** 4
- dentists**  
education of 297, 299, 301-304  
ST cessation counseling 297-304  
tobacco use intervention 331-332

- dependence on nicotine** 224, 229  
*(see also addiction to nicotine)*
- dependence on ST** 223-224, 227, 229, 239-244  
 comparison of snuff users and cigarette smokers 219-222, 227, 239-244  
 subjective 241-243  
*(see also addiction to ST)*
- desensitization of nicotine** 232-234
- diazohydroxides** 142, 144, 146, 149
- diglycerides** 191, 193, 195-196, 198-199
- 7,12-dimethylbenz[*a*]anthracene (DMBA)** 135, 153, 202, 204  
 transplacental carcinogen 162, 166
- dimethyl sulfoxide (DMSO)** 191, 193-199
- Division of Cancer Prevention and Control, NCI**  
 tobacco use intervention 331
- DNA**  
 adducts 128, 138, 141-143, 146, 148-151, 166, 168, 179  
 amplification 121-122, 178, 184-186  
 cellular 204, 209-211  
 HPV 175-180, 183-189, 202-203, 206, 208-211, 213-214  
 oncogene amplification 129  
 transfection assays 119-120, 137-138  
 tumor tissue 133-134  
 viral 203-204, 206, 208, 211, 213-214
- dopamine** 229, 234-235
- dot blot hybridization** 130-132, 176-177, 184-185, 188
- drug addiction, compared with nicotine** 291-292
- drug dependence criteria** 223
- dry snuff** 3-4, 8, 23, 62, 96, 101-103, 239  
 use by women 92  
 use in Great Britain 240  
*(see also nasal snuff)*
- dysplasia, ST-associated** 66-71, 76, 91, 93, 175-181, 183-185, 187, 298
- dysplastic lesions, oral** 53-54, 59, 63
- education, ST use** 247-256, 297, 304, 342, 344-345  
 by dental professionals 297-298, 303-304  
 in schools 342, 344-345  
 medical and dental professions, tobacco use intervention 331-332  
 of dental professionals 297, 299, 301-304  
 of health professionals 342  
 prevention/cessation 297, 301, 304  
 prevention in India 19, 24, 57, 307-311  
 public 341-342, 345
- educational levels of ST users**  
 baseball players 27-28  
 India 22-23  
 Sweden 76
- endocrine effects of nicotine** 226
- epidemiological studies of oral cancer risks** 11
- epithelial atrophy** 55-56, 58-59
- epithelial atypia** 207
- epithelial cell expression** 68-69
- epithelial changes in oral lesions** 66, 68-70  
 snuff and chewing tobacco compared 69
- epithelial dysplasia** 53-54, 59, 63, 67-71
- epithelial tissue, effects of nicotine**
- epithelial tumors** 109  
*(see also oral epithelial cells)*
- erythroplakia** 42
- erythroplasia** 91, 93
- esophagus, cancer of** 109, 150, 192
- European Community (EC)**  
 Council Directives 325, 327  
 ST policy and legislation 315, 321, 323, 326-328
- Fagerstrom Addiction Scale** 285
- fatty acids** 191, 197-200
- fear arousal in smoking and ST prevention** 261, 266
- Federal government, tobacco control** 343-344, 347-348
- Federal Trade Commission Report to Congress 1991, ST sales and advertising** iii
- females**  
 cigarette smoking ix  
 health effects of ST use, India 52-53, 56-58, 60  
 oral cancer incidence and mortality 12-13  
 oral cancer, ST use 91-92  
 prevalence of ST use 5, 8, 12, 15, 268, 317  
 ST use in India 19-21, 23  
 ST use in North Carolina 23
- fetus**  
 sensitivity to carcinogens 161-163, 165
- field cancerization** 91-92, 94
- First European Conference on Tobacco Policy** 320, 326, 328
- First International Conference on Smokeless Tobacco (1991)** iii, xiv, 337-338, 346
- floor-of-mouth mucosa, effect of nicotine on** 156, 158-159
- floor-of-mouth tumors** 123-124, 129
- Food and Drug Administration** 294, 328
- formaldehyde** 98-100, 111-112, 142, 176
- 4-H Club, ST prevention programs** 249, 253, 268, 331, 344
- FreshStart Adult Smoking Cessation Program** 280, 292-293
- gender of ST users**  
*see females; males*
- gene amplification** 121, 125, 128, 131, 137
- genes**  
*β*-actin 210, 212-213  
*herpes simplex virus* 202-207, 211  
*myc* 210
- genetic mutations, role in oral cancer** 135-136, 179
- gingiva**  
 effect of nicotine on 156-157, 159
- gingival index** 79-80, 82

- gingival recession from ST use** 74-76, 78-79, 82-86, 282, 297, 339
- gingivitis** 41, 78, 82, 84, 282, 297, 339
- governments, role in tobacco control** 320, 343-344, 347-348
- Great Britain, ST use** 240, 242
- gudakhu** 23, 51, 62
- gum cancer** 11-14
- hamster buccal pouch cells** 193, 195-196, 202-208
- Happy Days** 285
- Hawken** 30-31, 33, 36, 44-46, 48, 285
- head and neck cancers** 11
- head and neck tumors, oncogenes** 119, 123, 125
- health consequences of nicotine exposure** 219, 225-227
- health consequences of ST use, knowledge of** 11, 15-17
- health education** 247-256, 266
- health educators, ST control** 344
- health effects of smoking** 219, 225-227
- health effects of ST use** 41-49, 219, 225-227, 247, 279, 282, 298, 337-339
- baseball players 67
- baseball players' perception of 26, 33, 35-36
- India 21, 23-24
- Sweden 74-76
- health services professionals** 342, 344
- health warning labels** iii, xiv, 4, 11, 247, 279, 318-320, 327-328, 346, 348
- HeLa cells** 210-211, 214
- hemoglobin adducts** 142, 146-151, 166, 168
- herpes simplex virus (HSV)** 51, 63, 109, 111 and Ba[P] 202, 204-211
- cocarcinogenicity 202, 204, 206-207, 211
- Hispanics, baseball players, ST use** 28, 32, 34, 81
- Hispanics, ST use** 268, 270
- histopathologic studies of ST oral lesions** 66-67, 69-70
- historical overview of tobacco use** xxxix
- history of ST use, North America** xxxix, 3-4
- HLA-D gene products** 67-68
- Houston Little League project** 268-273
- How To Help Your Patients Stop Smoking** 332
- How To Help Your Patients Stop Using Tobacco** 332
- human oral tissue**
- metabolism of NNN and NNK in 141, 146-151
- human papillomavirus (HPV)** 51, 63, 68, 71-72
- DNA 175-180, 183-189, 202-203, 206, 208-211, 213-214
- L1 consensus sequence primers 183-186
- relationship to oral cancer and dysplasia 175-181, 183-185, 187, 203
- role in oral carcinogenesis 202-214
- hybridization** 123, 176-177
- dot blot 130-132, 176-177, 184-185, 188
- in situ 132, 231
- Northern blot 130, 132, 137, 206, 209, 212-214
- Southern blot 120-122, 129-130, 137, 176-177, 204, 206, 209-210, 213
- hydrazine** 96, 99-100, 112
- 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)** 142-144, 146-150
- α-hydroxylation of NNN and NNK** 142, 144-146
- hypercholesterolemia** 225-226
- hyperkeratosis** 42, 66, 69, 154-155, 177, 207-208
- hyperlipidemia** 225-226
- hyperorthokeratosis** 54, 66, 68-69, 177, 179
- hyperparakeratosis** 54, 66, 68-69, 178-179
- hyperplasia** 66, 68-69, 71, 109, 155, 183-185, 187, 207-208
- hypertension** 225-226
- in situ hybridization** 132, 176-177, 184-185, 231
- India**
- oral cancer 128, 135, 137-138
- smoking 51, 53-54
- tobacco chewing 128, 135-136, 138
- tobacco consumption 51, 60
- tobacco habits 307-311
- India, ST use** 19-25, 51-63
- advertising and promotion of ST products 19, 22-23
- betel quid chewing 51-62
- chewing tobacco 51-52, 60
- education/intervention 24, 57-58
- female/male use 19-21, 23
- health effects 23-24
- marketing of ST 19, 22-23
- oral cancer 51-53, 56-63
- oral lesions 51-62
- prevalence of 19-21, 51-53, 60
- snuff 51, 53, 62
- tobacco consumption 19-23
- types of ST used 20-23, 51
- International Agency for Research on Cancer (IARC)** xii, 111-112, 326, 339
- International Union Against Cancer** 321
- intervention programs** xiv, 280-281
- ASSIST 331, 333
- COMMIT 331, 333
- design of 261-273
- India 24, 57-58, 307-311
- National Cancer Institute 330-333
- physicians and dentists 331-332
- recommendations 338, 341-348
- role of dentists 286-287, 297-304
- (see also **cessation; prevention**)
- intracellular signaling** 191, 198
- intraoral soft tissue loss** 94
- Ireland, control and prevention of ST** 323-328
- anti-ST legislation 323-325, 327-328

- education and information program 324  
litigation 325-327
- "Just Say No"** 260, 267, 272
- keratinization** 68, 71
- keratinocytes, oral** 203, 207-214
- keratoses, ST** 183-185, 187
- keto acid** 142, 144-145, 164
- khaini** 20-21, 51, 61
- kidney, cancer of** 175
- knowledge of ST health risks** 11, 15-17, 341-342
- Kodiak** 285
- koilocytic cells** 68
- koilocytosis** 176
- L1 consensus sequence primers** 183-186
- lactones** 96
- Langerhans cell changes in ST users** 66, 68-69, 71
- larynx, cancer of** 111, 121-123
- Laswell's social-communication model** 264, 266
- Latinos**  
*see* **Hispanics**
- legislation** 11, 247, 317-318  
Ireland 323-328
- lesions, oral, ST-associated** 11, 13, 36, 91, 139, 155, 157, 175, 177-178, 181, 183, 187, 189, 282, 292  
baseball players and ST use 41-49, 66-72, 78-85  
incidence of in India 307-308, 310-311  
mucosal 66-67, 69, 71, 74-76, 78-86  
patterns 80-81  
precancerous, India 307-308, 310-311  
regression of 310  
site of 74-76, 78, 80-81  
Sweden 74-76
- leukoplakia**  
in baseball players 42, 45-49  
prevalence 14-15  
transformation to carcinoma 14-15, 17  
ST use 36, 66, 72, 91, 93-94, 128, 132, 138-139, 155, 177, 279, 282, 297-298, 339  
ST use, India 53-62
- Levi Garrett** 4, 28, 30, 33, 46, 48
- lip canal methodology** 109
- lipid assays** 194-195
- lipids** 191-200
- Little League** 331, 342, 344  
ST preventive education 249, 253  
ST use prevention program 260, 268-273
- liver tumors** 111, 113, 115, 162
- loose-leaf chewing tobacco** 3-4, 8, 96
- lung cancer** ix, 115, 135, 138, 150, 162, 164
- lymph node metastasis** 129, 132-133
- mainpuri tobacco** 20, 51-53, 60
- Major League Baseball, Office of Commissioner**  
ST education 298
- Major League Baseball players, ST use** iv, 26-36, 41-49, 67, 79, 222, 224, 268-269, 271
- maleic hydrazide diethanolamine (MH-30)** 105
- males**  
cigarette smoking ix  
health effects of ST use, India 52-54, 56-58, 60  
knowledge of ST risks 15-16  
oral cancer iii, 13-14, 91  
ST use iii-iv, x-xi, 5, 8, 15, 252, 268, 279, 281-282, 288, 315-317, 330  
ST use, India 19-21  
ST use, Sweden 74-76  
tobacco use, India 19-21
- malignant transformation of lesions** 14-15, 17, 53, 56-57, 59-60, 66, 71, 74, 76, 92-93, 128, 137, 139, 153, 165, 298
- Mammoth Cave** 4
- mandibular buccal surfaces** 80-85
- mandibular resection** 94
- market research** 252
- marketing of ST** x, 4, 7, 8, 247, 249-253, 255-256, 316, 318-320, 328  
India 19, 22-23  
snuff 247, 251, 255
- marketing of ST prevention programs** 249-256
- Masterpiece Tobacs** 328
- mawa** 20, 22, 51-52, 61-62
- McGuire's information-processing communication model** 264, 266-267
- mecamylamine** 230-231
- medical profession, tobacco use intervention** 332
- mesolimbic dopaminergic neurons** 229, 234-235
- metabolic activation pathways of NNN and NNK** 141-146, 149-151
- metabolic effects of nicotine** 226
- metachronous malignant oral lesions** 93
- methylation in NNK tumorigenesis** 144
- 3-methylcholanthrene (MC)** 162
- O<sup>6</sup>-methylguanine** 136, 142-144, 164, 166, 168, 176
- 4-(methylnitrosamino)butyric acid (MNBA)** 99, 101-102, 106, 112-113
- 3-(methylnitrosamino)propionic acid (MNPA)** 99, 101-102, 106, 112-113
- 4-(methylnitrosamino)-4-(3-pyridyl)butanol** 102
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (iso-NNAL)** 102, 104, 112-114, 142-146, 164
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butaneone (NNK)** 99, 102-104, 106, 109, 112, 115-116, 136, 141-151, 153, 161, 164-168, 175, 202  
metabolic activation of 141-146, 149-151

- perinatal carcinogenesis 161, 164-168  
transplacental bioassays 164-168  
tumorigenesis 141-146, 149-151
- 4-(methylnitrosamino)-4-(3-pyridyl)butyric acid (iso-NNAC)** 101-102, 104, 113-114
- minor league baseball players, ST use** iv, 67, 79
- mint snuff substitute** 283-284, 287
- mishri** 23, 51, 53-54, 62
- model of ST-related oral cancer** 179-180
- moist snuff** 3-4, 8, 92, 96-97, 101-103, 105-106, 239, 241-242, 279, 337-338  
ban in Ireland 323  
ban in U.K. 328  
consumption of x, xiii  
E.C. restrictions 321  
marketing of 247, 251, 255  
nicotine absorption from 219-221  
nicotine content in 219  
sales iii-iv  
use in Sweden 74-75
- mortality from oral cancer** 12-13
- mortality from tobacco use, India** 24
- mucosal cancers** 176, 183, 187
- mucosal lesions** 41-49, 51-62, 66-67, 69, 71, 74-75, 78-86
- mutations, oral cancers** 135-136, 176, 179-180
- myc gene** 210
- myc oncogenes** 125, 128-129, 132-133, 136-137
- myc proto-oncogene** 202, 206, 210, 214
- nasal cavity, cancer of** 109, 115, 150, 192
- nasal snuff** 19, 23, 74, 101-102  
addiction to 239  
consumption 315  
nicotine absorption 220, 240  
(*see also snuff*)
- National Cancer Advisory Board resolution on ST** x
- National Cancer Institute**  
ASSIST xiv, 331, 333  
collaborative intervention and prevention efforts iv, 330-333  
COMMIT 298, 331, 333  
Division of Cancer Prevention and Control 331  
First International Conference on ST xiv  
mission and mandate 320, 333  
monograph on ST (1989) xiv  
NCI/NIDR workshop on ST (1991) 337-340  
reduction of tobacco use 330-333  
smoking intervention programs xiv  
Smoking and Tobacco Control Program (STCP) x, 330  
ST use prevention programs 249, 260, 268, 287, 298
- National Center for Health Statistics** 15
- National Health and Nutrition Examination Survey** 15
- National Health Interview Survey (NHIS)** 15
- National Institute of Dental Research**  
NCI/NIDR workshop on ST (1991) 337-340
- Native Americans**  
ST cessation 287-288  
ST use 3, 5, 8, 35, 253, 268, 270, 331, 340, 346  
tobacco use ix
- NCI**  
*see National Cancer Institute*
- NCI/NIDR workshop on control of ST (1991)** 337-340
- neonates, effects of ST use on**  
sensitivity to carcinogens 165-166
- neoplasia**  
role of HPV 176, 183, 189
- neoplastic changes** 128, 187
- N-ethylnitrosourea (ENU)** 162
- Nicorette** 221, 281
- Nicotiana** 96-97, 101, 113
- nicotine**  
absorption from nicotine gum 294  
absorption from ST and cigarettes xiv, 219-222, 239-242, 282-283, 285, 291-292, 294, 298  
actions in CNS 226, 229-235  
addiction, measurement 285  
addiction to and dependence on iii, 219-224, 227, 229-230, 233, 236, 239-242, 279, 282-283, 291-293, 330, 339-340  
blood levels of 219-224, 226-227, 236, 239-242  
brain 291  
cardiovascular effects 219, 225-226  
cigarette smoking 219-223, 229-230, 233, 239-242  
content of ST products 284, 292-293  
desensitization of 232-234  
effects on oral mucosa 153-159  
fading procedures 279, 284  
health consequences 219, 225-227  
in CNS 291-292, 294  
in ST 104, 106, 115, 176, 219-223, 239-242  
metabolic and endocrine effects 226  
pharmacology of 219-224, 229-235  
psychoactive effects 223, 230  
reinforcement effects 223, 229-230, 234-236  
role in ST carcinogenesis 115, 153-159, 176  
withdrawal 219, 223, 239, 243-244, 292
- nicotine blockade therapy** 229, 236-237
- nicotine polacrilex gum** 219, 235, 239, 244, 279, 281, 284, 287, 291, 293-295, 297, 299, 304  
absorption of nicotine 221  
gingival response 157, 159
- nicotine reduction therapy** 284, 291, 293, 295, 299, 304
- nicotine replacement therapy** 229, 235-237, 332
- nicotine transdermal patch**  
*see transdermal nicotine patch*
- nicotine withdrawal** 292
- nicotinic receptors** 230-234

**NIH Consensus Development Conference on Smokeless Tobacco (1986)** xii, 4, 279, 337-340

**NIH3T3 assays** 120, 130, 136

**1947 Health Act (Ireland)** 325

**nitrosamines** xiv, 99, 102, 109, 112, 135-136, 138, 141, 145, 150, 162-164, 175, 191-192, 198  
organ-specific carcinogenicity 113-114

**nitrosamino acids, in ST** 99-102, 105-106, 112-113

**nitrosoazetadine-2-carboxylic acid** 99, 112

**nitrosoproline** 113

**nitrosothioproline** 113

**N-nitrosamines** xiv, 96, 100-102, 112-115, 347

**N-nitrosoanabasine (NAB)** 99, 102-104, 106, 112-114, 164, 176

**N-nitrosoanatabine (NAT)** 102-104, 106, 113-114, 164, 176

**N-nitrosodiethanolamine (NDELA)** 99-100, 105, 112, 114

**N-nitrosodiethylamine (NDEA)** 162, 164

**N-nitrosodimethylamine (NDMA)** 99, 101, 106, 112-114, 165  
fetal and neonatal carcinogen 161-162, 166-168

**N-nitrosomorpholine (NMOR)** 99, 101, 105, 112, 114

**N-nitrosonornicotine (NNN)** 99, 102, 104-106, 109, 112-115, 136, 141-146, 148-151, 153, 164, 175, 191-200, 202  
metabolic activation of 141-146, 149-151

**N-nitrosopiperidine** 99, 112, 114

**N-nitrosoproline (NPRO)** 102

**N-nitrosopyrrolidine (NPYR)** 99, 101, 106, 112, 114

**N-nitrososarcosine (NSAR)** 99, 101-102, 106, 112-113

**non-PKC phosphotransferase activity** 191, 195, 197-198

**North America, history of ST use** 3-4

**Northern blot hybridization** 130, 132, 137, 206, 209, 212-214

**nude mouse tumorigenicity assays** 120, 136, 137

**Office on Smoking and Health** xii, xiv

**oncogene amplification, head and neck tumors** 123, 125

**oncogene amplification, oral cavity carcinomas** 146

**oncogenes**  
head and neck tumors 119, 123  
*myc* 125, 128-129, 132-133, 136-137  
*ras* 119, 123, 125, 128-129, 131-132, 134-137, 179-180  
transplacental 163

**oncogenes in oral cancer** 128-139  
aberrations 130, 137  
amplification 121, 123, 125, 129-132, 134, 136, 138, 146  
expression 128-129, 132, 135  
*myc* and *ras* families 134, 136, 138

**opportunistic viruses** 67, 72

**oral cancer**  
alcohol use 135, 137, 175, 179-181  
and snuff use, Sweden 76  
and snuff use x, xii, 66, 70  
causative factors in ST 149  
epidemiological studies of risks 11  
genetic mutations 128-130, 134-135, 137-138, 179  
genetic predisposition 133  
histopathologic studies 66-67, 69  
incidence and mortality 12-14  
incidence, India 23-24, 307-309  
knowledge of risks 11, 15-17  
link with snuff use 247  
model for development of 179-180  
oncogenes 128-139, 146  
pathogenesis of 135, 138, 175-181  
role of HPV and HSV (viruses) 202-214  
site of 21  
ST-associated iii, x, 11-15, 66-67, 69-72, 75-76, 337-338, 345  
ST-associated, India 51-53, 56-63

**oral cancer, non-ST-related** 175, 178-179

**oral carcinogenesis** 128, 131, 134, 138, 141  
role of viruses 202-214

**oral cavity carcinoma**  
bioassays 109-110  
squamous cell 109-110, 135-136  
(*see also oral cancer*)

**oral cavity tumors**  
role of NNN and NNN 109, 115, 146, 150-151

**oral dysplasia**  
*see dysplasia, ST-associated*

**oral effects of ST use** 67, 78-86

**oral epithelial cells**  
response to tobacco exposure 175-176, 191-193, 198, 200

**oral keratinocytes** 203, 207-214

**oral lesions** 66-72, 74-75, 78-86, 91, 155, 157, 175, 177-178, 181, 183, 187, 189  
mucosal 13  
prevalence 15  
ST-associated 11-16, 36, 279, 281-283, 297, 332  
ST-associated, India 51-63

**oral lichen planus** 59-60

**oral moist snuff**  
use in Sweden 74-75

**oral mucosa** 187  
effect of nicotine 153-159

**oral mucosal lesions** 66-67, 69, 71, 78-86  
of baseball players and ST use 41-49  
ST use, India 51-62

**oral snuff** 19, 23, 338  
addiction to 219-224, 239, 241-242  
dry 96, 101  
moist 96-97, 101  
nicotine absorption 220-222, 241  
types of, U.S. 96

- (*see also snuff*)
- oral submucous fibrosis** 23
- oral tissue**  
metabolism of NNN and NNK in, human and rat 141-151
- P.L. 99-252** 298, 303
- packaging of ST products** 255
- pan chewer's lesion** 52, 61
- pan masala** 20, 22, 51, 62
- pancreas, cancer of** 109, 135, 161, 175
- papillomas** 109
- papillomavirus**  
*see* **human papillomavirus**
- pathogenesis of oral cancer** 135, 138, 175-181  
role of HPV 175-181
- pattiwala** 61
- peptic ulcers** 219, 225-226
- perception of ST health effects** 3, 26  
baseball players 26, 33, 35-36
- perinatal ST carcinogenesis** 161-169
- periodontal effects of ST use** 74-76, 78-86
- periodontitis** 78-79, 84, 297
- peripheral nervous system, nicotine action in** 230-231
- pharmacological adjuncts for ST cessation** 291, 295
- pharmacology of nicotine addiction** 219-224, 229-235, 240-241
- pharmacology of ST use** 219-224, 240-241
- pharmacotherapies for cessation of tobacco use** 235-237, 244  
(*see also cessation*)
- pharynx, cancer of** 11-12, 121, 123, 330
- phospholipids** 191, 195-200
- physicians, tobacco use intervention** 330-332
- placement of ST** 3, 11, 21, 52-54
- plasma cotinine levels** 220, 222-223, 282, 292-294
- plasma nicotine levels** 219-224, 226-227, 236, 239-242, 282-283, 285, 292-294, 298
- plug tobacco** 4, 8, 96, 103, 153
- point mutation** 128-130, 134-135, 137-138
- polonium-210** 96, 99-100, 112, 128
- polyadenylated RNAs** 202, 209-210, 212-213
- polychlorinated biphenyls (PCBs)** 165
- polycyclic aromatic hydrocarbons** 128
- polymerase chain reaction (PCR)** 123, 130, 134, 175, 177, 179, 183-189
- polynuclear aromatic hydrocarbons (PAH)** 97, 111, 162, 166-168
- porcine oral mucosa**  
effects of nicotine on 156-157
- preadolescent ST use prevention program** 269
- precancerous lesions** 11, 15, 139, 177, 187, 298  
ST-associated, India 24, 51-62, 307-308, 310-311  
*herpes simplex virus* 203  
(*see also* by type, e.g., **leukoplakia**)
- predisposition to smoking and ST use** 263-265
- prevalence of oral lesions**  
*see* **oral lesions**
- prevalence of ST use**  
*see* **smokeless tobacco use**
- preventive education and programs**  
adaptation of smoking prevention to ST 247, 249, 260, 268, 273  
baseball players iv  
cigarette smoking 247, 249, 260-263, 266-267  
for adolescents/school-based 248-249, 254, 342, 344  
India 19, 24, 57-59, 307-311  
marketing of 249-256  
NCI programs 330-333  
research 252-253, 260-273  
role of dentists 297-304  
ST use 247-256, 260-261, 268-273, 279, 287, 341-348  
(*see also intervention programs*)
- Prochaska-DiClemente model of readiness to quit** 285
- professional baseball**  
*see* **baseball players; Major League Baseball**
- promotion of ST products** 4, 7-8, 247, 249-253, 255-256  
control of 346-348  
India 19, 22-23  
tobacco companies vi
- promotion of ST prevention programs** 249-256
- protein kinase C**  
activity in oral epithelial cells 191, 193-199
- proto-oncogenes, head and neck tumors** 119, 123
- psychoactive effects of nicotine** 153, 159, 223, 230, 291-292
- psychosocial reasons for smoking and ST use** 263-265, 268-269
- public awareness of ST health effects** 279, 341-342
- public health cessation interventions** 280, 286-288
- pyridyloxobutylation** 142, 144
- quid placement**  
*see* **site of ST placement**
- quit ladder** 33, 35
- race of ST users** 80-81, 270  
baseball players 27-29, 32  
(*see also blacks; whites*)
- ras mutations, head and neck cancers**
- ras oncogenes** 125, 128-129, 131-132, 134, 136-137, 179-180
- rat oral tissue**  
activation of NNN and NNK in 144-146, 150-151
- receptors, nicotinic** 230-234
- recession, gingival** 74-76, 78-79, 82-86

- recommendations for control of ST** 337-348  
 First International Conference on ST 337-338, 346  
 NCI/NIDR workshop 337-340  
 WHO 340, 346
- Red Man** 4, 28, 30, 33, 46, 48
- reduction of tobacco use**  
*see intervention; prevention*
- regional use of ST** 5-8, 12, 252
- reinforcing effects of nicotine** 223, 229-230, 234-236
- relapse of tobacco use** 229, 236, 281, 283
- Renegades** 4
- reproduction, effects of ST use on** 23, 161-169, 225-226
- research**  
 smoking prevention 252-253, 261-268  
 ST prevention programs 252-253, 268-273
- research needs** 8, 16-17, 243-244, 339-340, 345-346
- restriction fragment length polymorphism (RFLP)** 133-134
- retinoic acid (RA)** 192-193
- risk groups for ST use** 3, 7, 340
- risk of cancer from ST use** 340, 345
- risk, perinatal, from ST use** 161-169
- risks for oral cancer**  
 case control studies 11  
 knowledge of 11, 15
- RNA** 130, 137  
 mRNA 129, 132  
 polyadenylated 202, 209-210, 212-213
- rodent fetal tumors** 161-163, 165
- roll tobacco** 96
- sachet ST** 3-4, 8, 220, 325
- sales of ST** iii-iv, 247, 251, 279
- Samson** 4
- schools**  
 health education 266  
 preventive ST education 248-249, 254, 279, 342, 344  
 smoking prevention programs 248, 261-262, 266-267
- seasonal use of ST compared to year-round use** 26, 29, 31-36
- seasonality of ST use** 41-49
- self-help cessation manuals and programs** 287-288, 293
- serum cotinine levels** 220, 222-223
- serum cotinine levels of baseball players** 26-27, 29, 31-36
- serum nicotine levels** 219-224, 226-227, 236, 239-242
- Seventh World Congress on Tobacco and Health** 337
- site of oral tumors** 91
- site of ST placement** 3, 11, 21, 52-54, 71, 74-76, 78, 80, 84, 92
- Skoal** 4, 28, 30, 33, 44, 46, 48-49, 285
- Skoal Bandits** 4, 220, 255, 325
- smokeless tobacco (ST)**  
 advertising/promotion iii, vi, ix-x, xii, 318-320  
 ban on ST advertising iii  
 brands 4, 41-42, 44-46, 49  
 brands used by baseball players 26-31, 33, 36  
 carcinogenesis 109, 153-159  
 carcinogens in 66, 96-97, 105, 111, 115, 161, 163-169, 175-176, 192  
 chemical composition 96-97  
 commerce, ban and control of 318-319, 323  
 control of 247, 315-319, 337-348  
 historical overview ix-xi, xxxix, 3-4  
 legislation 317-318, 323-329  
 manufacture 315-316, 318, 321  
 marketing and promotion of x, 247, 249-256, 316, 318-320, 328  
 marketing of, India 19, 22-23  
 nicotine content 153, 159, 284-285, 292-293, 298  
 nitrosamines in 101-103, 105, 161-164, 192  
 NNN and NNK 102-103, 141-151, 161, 164-168  
 reduction of harmful agents 105  
 sale of iii-iv, 247, 251, 279, 315, 318-319  
 sports promotion of ST 4  
 substitutes 281-284, 287  
 taxation 248, 319, 347  
 tumorigenicity 97  
 types, India 20-23  
 types of 3, 8, 41-42, 44-46, 49  
*(see also chewing tobacco; snuff)*
- Smokeless Tobacco Act of 1986** 279
- smokeless tobacco (ST) use**  
 addiction to 32, 35, 219-224, 227, 239-244, 282-283, 285, 291-293  
 addiction to, pharmacology of 219-224, 240-241  
 adolescent use 3-4, 248-249, 251-253, 268-273, 279-280, 284, 287, 340-341  
 adverse health effects 219, 225-227  
 age of first use 45, 47  
 age of users 253-254, 268, 271, 338, 340-341  
 and alcohol use 135, 175, 179-181, 183, 188-189  
 and concomitant cigarette smoking 19-21, 27-28, 75, 224, 279, 283-284, 286-287, 292, 302-303, 330  
 and *herpes simplex* virus 109, 111  
 and oral cancer iii, x, 23, 94, 111, 113, 175, 179-180, 326, 330, 337-338, 345  
 as substitute for smoking 75  
 associated epithelial and Langerhans cell changes 66, 68-71  
 associated oral carcinomas, clinical profile 91  
 associated oral lesions 66-72, 74-76, 78-86  
 association with sports iv  
 athletes' use 222-223  
 Australia 315  
 baseball players iv, 26-36, 66-72, 78-86, 222, 268, 41-49  
 baseball players' use and associated oral lesions 41-49  
 blood nicotine levels 219-223, 240-242

- cancer sites other than head and neck 161  
cardiovascular effects 219, 225-226  
cessation of use 219, 223, 235-237, 243-244,  
    279-288, 291-295, 297-304, 341-348  
children iii  
China 315  
compared to cigarette smoking 135, 219-227,  
    239-244  
conferences and workshops on 337-340  
Denmark 316  
dental intervention 297-298, 301-304  
dependence on 223-224, 227, 229, 239-244  
duration of use 45-47, 66-68  
effect on athletic performance 223  
females 5, 8, 12, 15, 92, 94, 161, 268  
Finland 316  
Great Britain 240, 242  
health effects of use 23-24, 279, 282, 298, 337-339  
health hazards in developing countries 319  
HPV and oral cancer 175-180, 183-189  
India 19-25, 51-63, 307-311, 315  
intervention programs 24, 268-273, 297-304, 332,  
    337, 341-348  
intervention study, India 307-311  
Japan 315  
knowledge of health risks 11  
Langerhans cell changes 66, 68-69, 71  
leukoplakia 282, 297-298  
males iii-iv, x-xi, 5, 8, 13, 252, 254, 268, 279,  
    281-282, 288  
model of social psychological processes 265  
NCI role in reducing use 330-333  
nicotine absorption 219-223, 239-242, 282-283,  
    285, 292, 295, 298  
nicotine addiction 282-283, 285, 291-293  
nicotine effects 219, 223  
not a safe alternative to smoking iii, xiv, 339, 344  
oral cancer 11-13, 66-67, 69, 72, 91, 175-181, 247,  
    297  
oral lesions 91, 175, 177-178, 181, 332  
patterns of use 251, 338, 345  
perception as safe alternative to smoking ix, 268,  
    272, 279, 284, 302-303, 319, 330  
perception of habit 242-243  
perception of health effects 3, 15, 26, 33, 35  
perinatal risk 161-169  
periodontal effects 74-76, 78-86  
placement site 71, 74-76, 78, 80, 84  
preadolescent 269  
prevalence of lesions 41-49  
prevalence of use, U.S. iii-iv, v, x-xii, 3-7, 251,  
    254, 279, 315, 317, 330, 338  
prevention programs 260, 268-273, 279, 341-348  
prevention research 252-253, 268-273  
preventive education 24, 247-256, 260-273, 297,  
    301, 342, 344-345  
professional baseball players 26-36  
psychoactive effects 223  
quit attempts 33, 35, 282  
regional 5-7, 252, 338  
reproductive effects 23, 161-169  
restrictions on use 320, 324  
risk groups, North America 3  
risk reduction 340  
surveys 251-252, 254  
Sweden 74-76, 239, 241-242, 317  
withdrawal symptoms 223, 239, 243-244,  
    282-283  
worldwide consumption 315  
(*see also chewing tobacco; snuff*)
- smoking**  
*see cigarette smoking*
- Smoking and Tobacco Control Program (STCP)** x, xiv
- smoking cessation applied to ST cessation** 279, 281, 283
- smoking prevention programs** 247, 249,  
    260-263, 266-267  
adaptation to ST prevention 247, 249, 260, 268,  
    273  
adolescents 249, 260-263, 266-267  
development of intervention 261-267  
research 252-253, 261-268
- smoking tobacco**  
carcinogenic agents in 112, 176  
nicotine content 153  
perinatal effects 163
- snuff**  
addiction to 219-224, 239-243  
and oral cancer iii, 12-14, 66, 76, 151, 247  
and oral epithelial changes 66, 69  
associated lesions 67, 70, 76  
associated oral carcinoma, clinical profile  
baseball players 27-36, 41-49  
brands used by baseball players 27-31, 33, 36  
carcinogens in xiv, 96, 99-100, 112  
compared to chewing tobacco 26, 32-36, 66-67,  
    69, 71  
concomitant smoking 75  
description of 3  
dipping 74-75, 97, 103, 141, 148-151  
dry 23, 96, 101-103, 240, 242  
flavoring agents 97-98  
Great Britain 240, 242  
health effects of using 282  
increased cancer risk 115, 150, 175  
increased use 297  
India 19, 23, 51, 53, 62  
induction of oral tumors 109, 141, 149-151  
marketing of moist 247, 251, 255  
moist 96-97, 101-103, 105-106, 219-220, 239,  
    241-242, 279, 316, 337-338  
moist oral 74-75  
nasal 19, 23, 74, 101-103, 240, 315  
nicotine absorption 219-222, 240-242, 292, 294  
nicotine content 106, 153, 219

- nitrosamines in 101, 103, 105-106  
oral 19, 23, 220-222, 323, 325-326  
placement 3  
plasma cotinine levels 220, 222-223  
prevalence of use v, x-xi, xiii, 6, 254, 297, 316  
sales iii-iv  
substitutes 281, 283-284, 287  
Sweden 74-75, 239, 241-242  
TSNA in 105-106  
tumorigenicity of 97, 150  
types of, U.S. 3-4, 96, 103  
use by women 12, 94  
users compared to cigarette smokers 219-222, 227, 240, 242  
users' perception of habit 242  
*(see also smokeless tobacco)*  
**snuff-dipper's lesion** 155, 157  
**social communication models** 264, 266-267  
**social inoculation strategy** 260, 263, 267, 269  
**social psychological processes**  
    smoking-related model 264  
    ST-related model 264  
**sodium excretion in ST users** 225  
**soft tissue lesions** 11, 15  
    *(see also oral lesions)*  
**Southern blot hybridization** 119-122, 129-130, 137, 176-177, 204, 206, 209-210, 213  
**special populations, interventions** 270, 273  
**spitting tobacco** v, ix-x, xiv  
    *(see also smokeless tobacco)*  
**sporting events sponsored by tobacco companies** vi-vii  
**sports, association with ST** iv, vi-vii, x  
    *(see also baseball)*  
**sports associations, tobacco control** 345  
**sports, effect of ST on** 223  
**squamous cell carcinoma** 57, 109-110, 119, 122-123, 125, 129, 131, 134-136, 183-185, 187, 207  
**ST**  
    *see smokeless tobacco*  
**stain, dental, from ST use** 78-82, 84  
**staining, epithelial** 66, 68-69  
**states, prevalence of ST use** 3, 5-7  
**states, tobacco control** 343, 347  
**STCP**  
    *see Smoking and Tobacco Control Program*  
**submucous fibrosis** 58-59, 61-62  
**Sullivan, Dr. Louis** 337  
**Surgeon General**  
    *see U.S. Surgeon General*  
**Surveillance, Epidemiology, and End Results (SEER) program** 12-13  
**surveys**  
    adolescents 346  
    India, tobacco use 307-308  
    knowledge of health risks of ST use 15-16  
    Little League 269-273  
    of dentists 299-301  
    recommendations 345-346  
    ST use xii, xiv, 5-8, 15, 251-252, 254, 345  
**Sweden**  
    carcinogens in ST 105-106  
    ST use 3, 74-76, 239, 241-242, 315  
**synergistic causal agents of oral lesions**  
    alcohol and ST 135, 202  
    viruses and ST 202  
**tachyphylaxis** 232  
**tapkeer** 23  
**Tata Institute of Fundamental Research (India)** 307, 333  
**Tata International Symposium on the Control of Tobacco-Related Cancers and Other Diseases (1990)** 340  
**taxation of ST products** 248, 319, 347  
**12-O-tetradecanoylphorbol-13-acetate (TPA)** 191-200  
**Texas Education Agency** 272  
**tobacco**  
    cancer from use of 128, 134, 175  
    carcinogens in 99, 109, 112, 115, 136, 202, 211  
    cell response to 191-200  
    chemical composition 97  
    control of 340-348  
    industry 316, 330  
    new products 316  
    unusual use of 240  
**Tobacco Act (Ireland)** 324  
**tobacco companies**  
    advertising/promotion iii, vi, ix-x, 4, 7  
    expenditures vi  
    sales iii  
    sporting events, sponsorship vi-vii  
**tobacco control** 340-348  
    legislation 317  
    national, international 316-317, 321  
    program objectives 316, 333  
**tobacco-plus-lime mixture** 21, 52-54, 61  
**tobacco-plus-lime-user's lesion** 61  
**Tobacco Products Act (1978) (Ireland)** 325  
**Tobacco Regulations (1986) (Ireland)** 325  
**tobacco-related illness** 321, 323, 330-331  
**tobacco-specific N-nitrosamines (TSNA)**  
    99-100, 102-106, 109, 113-115, 128, 136, 202  
    perinatal effects 161, 163-165  
**tobacco use**  
    cessation 229, 235-237, 239  
    cessation and preventive education 297, 299  
    historical overview ix, xxxix, 3-4  
    India 10-23, 51, 58, 60, 307-311  
    intervention by dentists 297-304  
    interventions 297-304, 307, 330-332  
    mortality from 323  
    prevention programs 260-263, 273

- reduction/intervention, NCI 330-332
- tongue abnormalities and tumors** 13, 42, 56-59, 121, 129
- training, cessation counseling** 297, 299, 301-304
- training of health professionals, intervention** 332, 342
- transdermal nicotine patch** 235, 244, 284, 291, 293-295
- transfection assays** 123, 129, 136-138
- transformation rates, malignancy**  
*see* malignant transformation of lesions
- transnational tobacco companies** 316, 321
- transplacental carcinogens** 161-162, 164-166
- transplacental tumors** 163-165
- triglycerides** 191-192, 197-199
- tumor promoters** 191-192
- tumor site, ST-associated oral cancer** 91, 93
- tumorigenesis**  
metabolic activation of NNN and NNK 141-146, 149-151  
oral cavity 141, 150  
perinate 163
- tumorigenic agents in ST** 97
- tumorigenicity assays** 109, 136-137
- tumors, head and neck** 119, 123, 125
- tumors, oral** 110-111, 130, 192  
development of 94, 128, 153
- tumors, transplacental** 163-165
- twist chewing tobacco** 4, 8
- twist tobacco** 96
- U.S. Department of Health and Human Services**  
tobacco reduction goals 330, 337
- United Kingdom** 318, 328
- U.S. Environmental Protection Agency**  
ban on MH-30 105
- U.S. Public Health Service** 338, 340, 343-344
- U.S. ST consumption** 3, 315
- U.S. Surgeon General**  
report on smokeless tobacco (1986) iii, xii, xiv, 4, 11, 97, 239, 279, 323, 326, 337  
report on smoking (1988) 223  
report on smoking and health (1964) ix
- U.S. Tobacco Company** iii, 247, 253, 255
- U.S. tobacco consumption, figures of** v, xi, xiii
- U.S. Tobacco International, Inc.** 323, 325
- uranium-235, -238** 96, 99-100, 112
- urethan** 96-97, 111
- urinary bladder, cancer of** 109
- uterine cervix**  
cancer of 71-72  
papillomavirus 68
- verruciform lesions** 93
- verrucous carcinoma** 57, 184
- verrucous hyperplasia** 183-185, 187
- videotapes, use in interventions** 266-267, 271
- Vincent, Fay, Major League Baseball Commissioner** iv
- viral DNA** 203-204, 206, 208, 211, 213-214
- viruses**  
cofactors in tumorigenesis 150  
HPV 175-180, 183-189, 202-214  
*herpes simplex* 51, 63, 109, 111, 202-214  
role in oral carcinogenesis 202-214
- volatile aldehydes** 98-99, 111, 112
- volatile N-nitrosamines (VNA)** 100-101, 105-106, 113
- warning labels** iii, xiv, 4, 11, 247, 279, 318-320, 327-328, 346
- white patch**  
*see* leukoplakia
- whites**  
baseball players, ST use 27-29, 32, 34, 80-81  
oral cancer, ST use 91-92, 94  
ST use 3, 5, 7, 43, 270
- withdrawal from ST use** 223, 239, 243-244, 282-283, 292-293  
compared to cigarette smoking 243-244
- withdrawal symptoms** 282-283, 292-293
- workplace, ST control** 343
- workshops on ST** 337-340, 346
- World Health Organization**  
expert group 316, 318, 320  
ST control recommendations 96, 104-105, 109, 115, 315-316, 318, 320, 340, 346  
Study Group on Smokeless Tobacco Control 326, 328, 346
- year 2000 public health objectives** 340
- year-round ST use compared to seasonal use** 26, 29, 31-36
- year-round use of ST** 41, 44-49
- youth, ST use**  
(*see* adolescents)
- Youth Risk Behavior Surveillance System** 7